Phase I Study of Continuous Administration of Salvianolic Acid A Tablet

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This was a Phase I repeated incremental doses study in healthy volunteers. A total of 24 subjects was planned to be enrolled. This was performed according to a double blind, randomized, placebo controlled design and included two sequential dose groups of repeat doses. Each group enrolled 12 subjects on salvianolic acid A or placebo (ratio 9 experimental: 3 placebo) and received salvianolic acid A or placebo twice daily (90mg) or daily (180mg) for 7 days, and follow‐up to 3 or 4 days.
Epistemonikos ID: 9beaa06f246c9e4e19ea2a205c6476d28a554036
First added on: May 22, 2024